Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Idoxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 6/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 1.00 |
| ▸ | PDE1A | P54750 | 9/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 9/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 9/20 | 1.00 |
| ▸ | PSMB1 | P20618 | 7/20 | 0.89 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.89 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Idoxifene SCHEMBL19217 | 1.00 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| Idoxifene SCHEMBL3774574 | 1.00 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL8767418 | 0.95 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL8767423 | 0.95 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL8767419 | 0.95 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL29822053 | 0.94 | PSMB1 (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL7650156 | 0.94 | PSMB1 (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL15648408 | 0.94 | PSMB1 (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL7650153 | 0.94 | PSMB1 (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL30902018 | 0.94 | PSMB1 (1.00) | PDE1APDE1BPDE1CESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17403 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20260007620-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | UNIV DUKE (US) | 2026-01-08 | — | — | US | claimed |
| EP-4673152-A2 | COMBINATIONS FOR TREATMENT OF PARKINSON'S DISEASE AND OTHER PRIMARY AND SECONDARY PARKINSONIAN DISORDERS | Kenai Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| US-12509444-B2 | Compounds and methods for CD73 modulation and indications therefor | PLEXXIKON INC. (US) | 2025-12-30 | — | — | US | claimed |
| EP-4654969-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-03 | — | — | EP | claimed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | claimed |
| US-5770609-A | ADMINISTERING TAMOXIFEN DERIVATIVES TO INHIBIT SMOOTH MUSCLE CELL PROLIFERATION ASSOCIATED WITH VASCULAR TRAUMA FROM SURGERY OR TRANSPLANTATION OF ORGANS OR MEDICAL DEVICES | NEORX CORPORATION (US) | 1998-06-23 | — | — | US | claimed |
| EP-0843999-A1 | Use of estrogen agonists/antagonists for the manufacture of a medicament in the treatment of atherosclerosis independent of a lipid lowering effect | PFIZER INC. (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0833624-A2 | PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES WITH TAMOXIFEN ANALOGUES | NEORX CORPORATION (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1998009519-A1 | METHOD OF TREATING POST MENOPAUSAL DISEASES, INCLUDING OSTEOPOROSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-03-12 | — | — | WO | claimed |
| WO-1997046252-A1 | GROWTH HORMONE COMPONENT AND BONE ANTI-RESORPTIVE AGENT IN CYCLIC (COHERENCE) TREATMENT OF OSTEOPOROSIS | NOVO NORDISK A/S (DK) | 1997-12-11 | — | — | WO | claimed |
| WO-1997031640-A1 | COMBINATION THERAPY FOR OSTEOPOROSIS | PFIZER INC. (US) | 1997-09-04 | — | — | WO | claimed |
| WO-1997024369-A1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1997-07-10 | — | — | WO | claimed |
| WO-1996040098-A2 | PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES WITH TAMOXIFEN ANALOGUES | NEORX CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996035417-A1 | COMBINATIONS OF ANTI-OESTROGEN COMPOUNDS AND PKC MODULATORS AND THEIR USE IN CANCER THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-11-14 | — | — | WO | claimed |